MB-102 (Mustang Bio)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameMB-102 (Mustang Bio)
Drug Alias NameMB-102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionInterleukin-3 receptor subunit alpha modulatorsT lymphocyte replacements
TargetsInterleukin-3 receptor subunit alpha
Therapy Area/IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmNeoplasm, ResidualLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMustang Bio IncCity Of Hope National Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesMustang Bio IncCity Of Hope National Medical Center
Inactive CompaniesN/A
Active IndicationsBlastic Plasmacytoid Dendritic Cell NeoplasmNeoplasm, ResidualLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A